A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

NCT03417102 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A
Hemophilia B

Interventions

DRUG: fitusiran
DRUG: Bypassing agents

Sponsor

Genzyme, a Sanofi Company